Literature DB >> 1648025

Diagnostic value of measurement of serum type I procollagen carboxy terminal peptides in patients with scirrhous carcinoma of the stomach.

K Kohda1, N Ito, M Ohwada, K Morita, N Watanabe, Y Kohgo, Y Mogi, Y Niitsu.   

Abstract

We have evaluated the radioimmunoassay for type I procollagen carboxy terminal peptide (type I C-peptide), which is liberated from type I procollagen during its conversion to collagen, in the serodiagnosis of scirrhous carcinoma of the stomach. The mean (SD) serum concentration of type I C-peptide in 39 normal subjects was 41.7 (19.7) ng/ml. The mean serum values and the positive ratio of type I C-peptide in 11 patients with stages II and III scirrhous carcinoma of the stomach were 91.2 (41.9) ng/ml and 54.5%, respectively. In 10 patients with other types of gastric carcinoma, the mean type I C-peptide values were not significantly different from the normal value. Serum type I C-peptide values reflected the clinical course of scirrhous gastric carcinoma in five patients who underwent either operation or chemotherapy. The measurement of serum type I C-peptide concentrations could provide a useful way of diagnosing and monitoring scirrhous carcinoma of the stomach.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1648025      PMCID: PMC1378876          DOI: 10.1136/gut.32.6.624

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  11 in total

1.  Characterization of procollagen-derived peptides unique to the precursor molecule.

Authors:  W H Murphy; K von der Mark; L S McEneany; P Bornstein
Journal:  Biochemistry       Date:  1975-07-15       Impact factor: 3.162

2.  Antibodies to chick-tendon procollagen. Affinity purification with the isolated disulfide-linded NH2-terminal extensions and reactivity with a component in embryonic serum.

Authors:  P Dehm; B R Olsen; D J Prockop
Journal:  Eur J Biochem       Date:  1974-07-01

3.  Radioimmunoassay for human procollagen.

Authors:  M B Taubman; B Goldberg; C Sherr
Journal:  Science       Date:  1974-12-20       Impact factor: 47.728

Review 4.  Proteoglycans and the intercellular tumor matrix.

Authors:  R V Iozzo
Journal:  Curr Top Pathol       Date:  1987

5.  Radioimmunoassay for type III procollagen peptide and its application to human liver disease.

Authors:  H Rohde; L Vargas; E Hahn; H Kalbfleisch; M Bruguera; R Timpl
Journal:  Eur J Clin Invest       Date:  1979-12       Impact factor: 4.686

6.  Biosynthesis of an interstitial type of collagen by cloned human gastric carcinoma cells.

Authors:  K Sakakibara; T Suzuki; T Motoyama; H Watanabe; Y Nagai
Journal:  Cancer Res       Date:  1982-05       Impact factor: 12.701

7.  Enzymes of collagen synthesis and type III procollagen amino-propeptide in serum from Nigerians with hepato-cellular carcinoma and other malignant diseases.

Authors:  D M Bolarin; E R Savolainen; K I Kivirikko
Journal:  Int J Cancer       Date:  1982-04-15       Impact factor: 7.396

Review 8.  Aging of the extracellular matrix and its pathology.

Authors:  J Labat-Robert; L Robert
Journal:  Exp Gerontol       Date:  1988       Impact factor: 4.032

9.  Inappropriate production of collagen and prolyl hydroxylase by human breast cancer cells in vivo.

Authors:  M S Al-Adnani; J A Kirrane; J O McGee
Journal:  Br J Cancer       Date:  1975-06       Impact factor: 7.640

10.  Immunohistochemical identification of type I procollagen in tumour cells of scirrhous adenocarcinoma of the stomach.

Authors:  Y Niitsu; N Ito; K Kohda; M Owada; K Morita; S Sato; N Watanabe; Y Kohgo; I Urushizaki
Journal:  Br J Cancer       Date:  1988-01       Impact factor: 7.640

View more
  1 in total

1.  Quantitative analysis of serum procollagen type I C-terminal propeptide by immunoassay on microchip.

Authors:  Shouki Yatsushiro; Rie Akamine; Shohei Yamamura; Mami Hino; Kazuaki Kajimoto; Kaori Abe; Hiroko Abe; Jun-ichi Kido; Masato Tanaka; Yasuo Shinohara; Yoshinobu Baba; Toshihiko Ooie; Masatoshi Kataoka
Journal:  PLoS One       Date:  2011-04-13       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.